期刊文献+

唑来膦酸联合鲑降钙素对绝经后骨质疏松性骨折的影响 被引量:8

Effect of Zoledronic Combined Salcatonin on Postmenopausal Osteoporosis Fractures
原文传递
导出
摘要 目的研究唑来膦酸联合鲑降钙素对绝经后骨质疏松性骨折的影响。方法将60例绝经后脊柱压缩性骨折患者随机分为对照组和观察组,2组均口服维D钙咀嚼片,皮下注射鲑降钙素注射液,观察组在此基础上静脉滴注唑来膦酸注射液。治疗前和治疗6个月后,对所有患者进行腰锥的骨密度(BMD)测定,运用视觉模拟评分法(VAS)进行疼痛监测,用功能障碍指数(ODI)的变化来评价功能障碍改善情况。结果治疗6个月后,与治疗前相比,2组BMD、VAS评分、ODI均有所改善,差异有统计学意义(P<0.01)。与对照组相比,观察组的BMD增加,ODI下降更加明显,差异有统计学意义(P<0.05)。结论唑来膦酸与鲑降钙素联合用药具有增加绝经后骨质疏松症患者BMD,减轻患者疼痛,提高患者生活质量的作用。 OBJECTIVE To study the effect of zoledronic combined salcatonin on postmenopausal osteoporosis fractures.METHODS Sixty postmenopausal women of osteoporotic spinal compression fractures were randomly divided into control group and observation group.All the patients were treated by calcium supplement with vitamin D chewable tablets and salcatonin injection.The patients of observation group were intravenously injected zoledronic injection on the basis of before.The bonemineral density(BMD) of lumbar vertebra was measured after 6 months compared to before the treatment.The visual simulation score(VAS) and Oswestry disability index(ODI) was used to assess patients pain relief and dysfunction improvement.RESULTS After treatment of 6 months,the increase of BMD,the decrease of VAS and ODI was significant compared with before the treatment(P0.01).The increase of BMD and the decrease of ODI in observation group was significant compared with control group(P0.05).CONCLUSION The study reveales an increase in BMD,relief from pain and improvement quality of life follwing the treatment of zoledronic combined salcatonin in postmenopausal osteoporosis fractures.
机构地区 解放军第
出处 《中国现代应用药学》 CAS CSCD 2015年第3期355-358,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 骨质疏松症 唑来膦酸 鲑降钙素 osteoporosis zoledronic salcatonin
  • 相关文献

参考文献11

  • 1HUANG S, L1N H, ZHU X, et al. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis [J]. Endokrynol Pol, 2014, 65(2): 96-104.
  • 2XIE H, TAn L F, HE X B. Efficacy of sodium zoledronic joint salmon calcitonin treatment of elderly patients with primary osteoporosis [J].山西医药杂志, 2011, 40(10): 1027-1028.
  • 3ZHENG G X, ZHAO X O, LIU G L, et al. Oswestry disability index assess the credibility of low back pain patients [J]. 中国脊柱脊杂志, 2002, 12(1): 13-15.
  • 4KHAJURIA D K, RAZDAN R, MAHAPATRA D R. Drugs for the management of osteoporosis: a review [J]. Rev Bras Reumatol, 2011, 51(4): 365-371,379-382.
  • 5DIRSCHL D R, HENDERSON R C, OAKLEY W C. Accelerated bone mineral loss following a hip fi'acture: a prospective longitudinal study [J]. Bone, 1997, 21(1): 79-82.
  • 6MURAD M H, DRAKE M T, MULLAN R J, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis [J]. J Clin Endocrinol Metab, 2012, 97(6): 1871-1880.
  • 7KHAJURIA D K, RAZDAN R, MAHAPATRA D R. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarcbitecture and mechanical properties in osteopenic ovariectomized rats [J]. J Orthop Sci, 2014, 19(4): 646-56.
  • 8COSMAN F, KEAVENY T M, KOPPERDAHL D, Et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene [J]. J Bone Miner Res, 2013, 28(6): 1328-1336.
  • 9MUSCHITZ C, KOCIJAN R, FAHRLEITNER-PAMMER A, et al. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density [J]. J Bone Miner Res, 2013, 28(1): 196-205.
  • 10BINKLEY N, BOLOGNESE M, SIDOROWICZ-BIALYNICKA A, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis(ORACAL) trial [J]. J Bone Miner Res, 2012, 27(8): 1821-1829.

同被引文献58

引证文献8

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部